Literature DB >> 29395672

DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine.

Mariana Santos1, Simão Cruz2, João Peres2, Luís Santos3, Purificação Tavares4, Jorge Pinto Basto4, Vasco Salgado2, Ana Herrero Valverde2.   

Abstract

DOK7 congenital myasthenic syndrome (DOK7-CMS) generally presents early in life and is treated with salbutamol or ephedrine. This report describes an atypical case of a 39-year-old woman who presented with proximal upper limb weakness in the third trimester of pregnancy and was initially diagnosed with seronegative myasthenia gravis. Dramatic clinical worsening under pyridostigmine and further inefficacy of steroids, intravenous human immunoglobulin (IVIG) and plasma exchange (PLEX) led to the presumptive diagnosis of a CMS. Initially, a slow-channel CMS was regarded as more probable due to prominent finger extension weakness. Accordingly, fluoxetine was started and a lengthy improvement was seen. Clinical deterioration occurred after fluoxetine withdrawal, when a c.1124_1127dup homozygous mutation was detected in DOK7 gene. Afterwards, salbutamol was started and the patient became asymptomatic. This case highlights the importance of considering CMS before an adult-onset myasthenic syndrome and suggests a benefit from fluoxetine not previously reported in DOK7-CMS.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Congenital myasthenic syndrome; DOK7; Fluoxetine; Pregnancy

Mesh:

Substances:

Year:  2017        PMID: 29395672     DOI: 10.1016/j.nmd.2017.12.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  2 in total

1.  Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome.

Authors:  Rachel Thompson; Gisèle Bonne; Paolo Missier; Hanns Lochmüller
Journal:  Emerg Top Life Sci       Date:  2019-01-28

2.  Congenital myasthenic syndrome in China: genetic and myopathological characterization.

Authors:  Yawen Zhao; Ying Li; Yang Bian; Sheng Yao; Penju Liu; Meng Yu; Wei Zhang; Zhaoxia Wang; Yun Yuan
Journal:  Ann Clin Transl Neurol       Date:  2021-03-23       Impact factor: 4.511

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.